AMEX · Financial Statements

China Pharma Holdings, Inc. (CPHI) Revenue, Earnings & Financial Statements

$0.49 AMEX: CPHI Market Cap $21.27M

Data as of Nov 17, 2026 close · Statements through the quarter ended Jun 2026 · Source: Financial Modeling Prep (methodology)

China Pharma Holdings, Inc. most recently reported annual revenue of $4.0M, a net loss of $3.0M. Revenue declined at an average annual rate of 18.3% over the last 5 fiscal years. See the full income statement, balance sheet, and cash flow statement below, plus valuation and return ratios.

China Pharma Holdings, Inc.: Revenue fell from $16.0M in 2016 to $4.0M in 2025, a change of -75.0% over 9 years; net profit was positive in 0 of 10 reported years; operating margin moved from -26.9% to -74.5%, a shift of -47.6 percentage points; the most recent year shows a net loss of $3.0M.

Income Statement — 10 Years (USD millions)

Metric2016201720182019202020212022202320242025
Revenue$16.0M$13.0M$12.0M$11.0M$11.0M$10.0M$8.0M$7.0M$5.0M$4.0M
Operating Expenses$20.0M$18.0M$16.0M$14.0M$13.0M$13.0M$12.0M$10.0M$9.0M$7.0M
Operating Profit−$4.0M−$4.0M−$4.0M−$3.0M−$3.0M−$3.0M−$4.0M−$3.0M−$5.0M−$3.0M
Operating Margin-26.9%-34.0%-32.2%-31.0%-23.7%-29.7%-43.8%-39.3%-101.3%-74.5%
Other Income−$5.0M−$15.0M−$7.0M−$17.0M$0−$1.0M$0$0$0$0
Interest$1.0M$1.0M$0$0$0$1.0M$0$0$0$0
Depreciation$3.0M$3.0M$3.0M$3.0M$3.0M$3.0M$3.0M$3.0M$3.0M$2.0M
Profit Before Tax−$9.0M−$19.0M−$11.0M−$21.0M−$3.0M−$3.0M−$4.0M−$3.0M−$5.0M−$3.0M
Tax rate (%)-3.5%-0.6%1.0%0.0%0.0%0.0%0.0%0.0%0.0%0.0%
Net Profit−$9.0M−$19.0M−$11.0M−$21.0M−$3.0M−$3.0M−$4.0M−$3.0M−$5.0M−$3.0M
EPS−$2.11−$4.42−$2.47−$4.82−$0.72−$0.85−$1.94−$0.29−$0.27−$0.74

Quarterly Results — Last 12 Quarters (USD millions)

8 duplicate period labels in the source data were collapsed.

MetricSep '23Dec '23Mar '24Jun '24Sep '24Dec '24Mar '25Jun '25Sep '25Dec '25Mar '26Jun '26
Revenue$2.0M$2.0M$1.0M$1.0M$1.0M$1.0M$1.0M$1.0M$1.0M$1.0M$1.0M$1.0M
Operating Expenses$3.0M$3.0M$2.0M$2.0M$2.0M$2.0M$2.0M$2.0M$1.0M$2.0M$2.0M$2.0M
Operating Profit−$1.0M−$1.0M−$1.0M−$1.0M−$1.0M−$1.0M−$1.0M−$1.0M−$1.0M−$1.0M−$1.0M−$1.0M
Operating Margin-39.6%-55.1%-66.9%-150.4%-98.7%-105.5%-66.8%-63.6%-83.1%-97.9%-113.6%-151.0%
Interest$0$0$0$0$0$0$0$0$0$0$0$0
Profit Before Tax−$1.0M−$1.0M−$1.0M−$1.0M−$1.0M−$1.0M−$1.0M−$1.0M−$1.0M−$1.0M−$1.0M−$1.0M
Tax rate (%)0.0%0.0%0.0%0.0%0.0%0.0%0.0%0.0%0.0%0.0%0.0%0.0%
Net Profit−$1.0M−$1.0M−$1.0M−$1.0M−$1.0M−$1.0M−$1.0M−$1.0M−$1.0M−$1.0M−$1.0M−$1.0M
EPS−$0.16−$0.26−$0.20−$0.30−$0.23−$0.26−$0.18−$0.16−$0.17−$0.23−$0.27−$0.34

Over the 10 years reported for China Pharma Holdings, Inc., borrowings decreased from $11.0M in 2016 to $4.0M in 2025, cash stood at $0 in the latest year, shareholders' equity was $0, current assets covered current liabilities 0.29 times.

Balance Sheet — 10 Years (USD millions)

Metric2016201720182019202020212022202320242025
Total Assets$79.0M$60.0M$45.0M$22.0M$21.0M$23.0M$18.0M$16.0M$15.0M$31.0M
Current Assets$18.0M$12.0M$9.0M$6.0M$5.0M$9.0M$6.0M$6.0M$3.0M$2.0M
Cash$3.0M$2.0M$1.0M$1.0M$1.0M$5.0M$2.0M$1.0M$1.0M$0
Inventory$7.0M$6.0M$5.0M$4.0M$4.0M$3.0M$3.0M$4.0M$2.0M$2.0M
Receivables$4.0M$2.0M$1.0M$1.0M$1.0M$1.0M$0$1.0M$0$0
Fixed Assets$25.0M$23.0M$19.0M$16.0M$15.0M$13.0M$10.0M$7.0M$5.0M$5.0M
Capital Work in Progress$0$0$0$0$0$0$0$0$0$0
Investments$0$0$0$0$0$0$0$0$0$0
Other Assets$0$0$0$0$0$0$0$0$0$0
Total Liabilities$20.0M$17.0M$15.0M$13.0M$13.0M$17.0M$13.0M$9.0M$7.0M$8.0M
Current Liabilities$10.0M$9.0M$10.0M$10.0M$11.0M$11.0M$13.0M$7.0M$5.0M$7.0M
Borrowings$11.0M$10.0M$8.0M$7.0M$7.0M$12.0M$9.0M$5.0M$4.0M$4.0M
Other Liabilities$8.0M$7.0M$7.0M$6.0M$6.0M$4.0M$5.0M$4.0M$4.0M$4.0M
Equity$0$0$0$0$0$0$0$0$0$0
Reserves$59.0M$43.0M$30.0M$9.0M$8.0M$6.0M$4.0M$7.0M$8.0M$23.0M

For China Pharma Holdings, Inc., operating cash flow was positive in 4 of 10 reported years; free cash flow in the latest year was $0; free cash flow was positive in 3 of 10 years.

Cash Flow Statement — 10 Years (USD millions)

Metric2016201720182019202020212022202320242025
Operating Cash Flow$3.0M$1.0M$1.0M$1.0M$0$0$0−$1.0M$0$0
Investing Cash Flow$0$0$0$0−$2.0M−$1.0M−$1.0M$0−$1.0M$0
Financing Cash Flow$0$0$0$0$0$0$0$0$0$0
Net Cash Flow−$4.0M−$1.0M−$1.0M−$1.0M$0$4.0M−$3.0M−$1.0M−$1.0M$0
Free Cash Flow$3.0M$1.0M$1.0M$0−$1.0M−$1.0M−$1.0M−$1.0M−$1.0M$0

Valuation & Return Ratios

MetricValue
PEG Ratio0.02
EV / EBITDA-18.43
FCF Yield-1.05%
Quick Ratio0.08
Interest Coverage-44.20
Return 1Y-66.15%
Return 3Y-88.72%
Return 5Y-99.83%

China Pharma Holdings, Inc. (CPHI) financials — frequently asked questions

What is China Pharma Holdings, Inc.'s annual revenue?

China Pharma Holdings, Inc. (CPHI) reported annual revenue of $4.0M in its most recent fiscal year.

What is China Pharma Holdings, Inc.'s net profit?

China Pharma Holdings, Inc. (CPHI) reported a net loss of $3.0M in its most recent fiscal year.

What is CPHI EV/EBITDA?

China Pharma Holdings, Inc.'s enterprise value to EBITDA (EV/EBITDA) ratio is -18.43. A negative value means EBITDA was negative over the period, so the ratio is not a meaningful valuation measure.

Revenue and earnings of other Drug Manufacturers - Specialty & Generic stocks

TEVA revenue $17.3BZTS revenue $9.5BVTRS revenue $14.3BELAN revenue $4.7BRDY revenue $353.5BALKS revenue $1.5BAMRX revenue $3.0BLNTH revenue $1.5BSUPN revenue $719.0MBHC revenue $10.3BAll Drug Manufacturers - Specialty & Generic stocks

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)Eli Lilly (LLY)JPMorgan (JPM)

Related stock screens

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksHigh ROE StocksLow P/E StocksHigh Net Margin StocksDividend StocksLow Debt StocksAll stock screens
CPHI Overview CPHI Dividend Run Stock Screener

Data for information only, not investment advice. Figures may be delayed or inaccurate; verify against company filings. See our disclaimer.